BioSpace News Archive

Bristol-Myers Squibb announced that it has expanded its relationship with Flatiron Health, extending a three-year collaboration agreement.

Ahead of June’s annual American Society of Clinical Oncology meeting Merck said this morning that its Phase III lung cancer trial met a pre-specified secondary endpoint of overall response rate (ORR) in an early cohort of participants at an interim analysis.

According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.

Frequent sauna bathing is associated with a reduced risk of stroke, according to a new international study.

Topix Pharmaceuticals, Inc. has announced the launch of Glycolix Glyco-Urea KP Therapy.

Regeneron Pharmaceuticals, Inc. announced financial results for the first quarter of 2018 and provided a business update.

Teleflex Incorporated announced financial results for the first quarter ended April 1, 2018.

Lannett Company, Inc. announced its participation at two upcoming investor conferences.

The Canadian Medical Association (CMA), in partnership with the CMA Foundation, is launching the Healthy Canadians Grants program

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-407 trial investigating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel as first line treatment for metastatic squamous non-small cell lung cancer (sNSCLC) met a pre-specified secondary endpoint of overall response rate (ORR) in an early cohort of participants at an interim analysis